NYRADA INC. (ASX: NYR)
Health care · News and insights
Price unavailable
Latest NYR announcements
Announcement Insights
Nyrada Raises Fresh Capital As PROTECT-MI Trial Enrollment Advances
Nyrada raised approximately $1 million through its share purchase plan after a September placement, saying the funding would support Xolatryp as its Phase IIa trial progresses. By October 30, five patients had been dosed in PROTECT-MI, up from three at the previous update; the company targets final dosing in mid-2027 and preliminary results in the second half of 2027. Its US drug application submission remains targeted for the first half of 2027.
Updated 06 Nov 2026, 07:48 AM Sydney time
Sources
Quotation of Attaching OptionsUpdate - Proposed issue of securities - NYRQuotation of New OptionsChange of Director's Interest Notice - JMUpdate - Proposed issue of securities - NYRNotice of Initial Substantial Holding - J MoorePROTECT-MI Phase IIa Clinical Trial Update No 4Application for quotation of securities - NYRApplication for quotation of securities - NYRSecurities Purchase Plan ResultsComments
2026-11-05 · Health care
NYR: $0.445 +2.30% · MC: $133M
Nyrada’s options issued to non-director participants in its recent capital raising begin trading under the ticker NYRO, following its application for quotation earlier this week. Each option can be exercised for a depositary interest and a further option, which will not be granted until the initial exercise period ends. Directors’ participation in the raising remains subject to security holder approval at a meeting expected in February.
Updated 2026-11-05 10:25
Sources
Quotation of Attaching OptionsComments
2026-11-04 · Health care
NYR: $0.435 -10.31% · MC: $133M
Nyrada has pushed the proposed allotment of options for lead manager Bell Potter to March 2027, pending shareholder approval for the related-party portion of its capital raising. The maximum number of options has been reduced from approximately 3.9 million to approximately 3.5 million, based on the completed placement and share purchase plan results and assuming approval of the maximum related-party participation.
Updated 2026-11-04 16:31
Sources
Update - Proposed issue of securities - NYRComments
2026-11-03 · Health care
NYR: $0.485 +7.78% · MC: $133M
Nyrada has applied to list approximately nine million options issued free to participants in its placement and security purchase plan, following its quotation application lodged last week. Each option can be exercised for a depositary interest and a further option, although the latter will not be granted until the initial exercise period expires. The company will announce the options ticker once quotation is completed.
Updated 2026-11-03 12:44
Sources
Quotation of New OptionsComments
2026-11-02 · Health care
NYR: $0.450 -2.17% · MC: $133M
Nyrada chair John Moore acquired 5 million CDIs off-market, increasing his holding from about 9.5 million to about 14.5 million and making him a substantial holder with 5.58% voting power. Separately, Nyrada reported five patients dosed in its PROTECT-MI trial, up from three at its previous update, with final dosing still targeted for mid-2027.
Updated 2026-11-02 15:18
Sources
Change of Director's Interest Notice - JMUpdate - Proposed issue of securities - NYRNotice of Initial Substantial Holding - J MooreComments
2026-10-30 · Health care
NYR: $0.460 -6.12% · MC: $133M
Nyrada says five patients have now been dosed in its PROTECT-MI Phase IIa trial, up from three at its previous update, with five sites active and three more expected to open by the end of November. The company is targeting final patient dosing in mid-2027 and preliminary results in the second half of 2027, while its US drug application submission remains targeted for the first half of 2027. Separately, Nyrada has issued the CDIs and attaching options associated with its recent capital raising.
Updated 2026-10-30 10:10
Sources
PROTECT-MI Phase IIa Clinical Trial Update No 4Application for quotation of securities - NYRApplication for quotation of securities - NYRComments
2026-10-28 · Health care
NYR: $0.495 +2.06% · MC: $133M
Nyrada raised approximately $1 million before costs through its securities purchase plan and plans to issue new CDIs on 30 October. Participants will also receive attaching options, alongside options linked to the company’s September placement; Nyrada says it is well-funded to advance Xolatryp, whose Phase IIa trial has commenced.
Updated 2026-10-28 09:00
Sources
Securities Purchase Plan ResultsComments
Comments